Essity Concludes Strategic Review of Consumer Tissue Private Label Europe Business

Print this Article | Send to Colleague

The Consumer Tissue Private Label Europe business remains a part of the Essity Group and thereby the strategic review of the division, which began on April 26 of this year, is concluded.

Essity continuously evaluates its various businesses to increase long-term value creation. In the strategic review of Consumer Tissue Private Label Europe it was concluded that the business as a result of the implemented divisionalization, is a competitive and value-creating part of Essity.

Net sales for the Consumer Tissue Private Label Europe business amounted to approximately SEK 9.8bn in 2022. The business encompasses seven production facilities in Belgium, France, Germany and Italy with approximately 1,900 employees.

Back to Tissue360 Newsletter